It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

Pfizer

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
In China, no easy way to get Pfizer's COVID drug Paxlovid

Asia Pacific Jan 16, 2023

In China, no easy way to get Pfizer's COVID drug Paxlovid

Beijing has acknowledged that supplies are still insufficient to meet demand, even as millions of courses of the treatment were shipped to the country recently.

Pfizer's bivalent vaccine linked to rare strokes in older people in preliminary U.S. data

World / Science & Health Jan 14, 2023

Pfizer's bivalent vaccine linked to rare strokes in older people in preliminary U.S. data

The early finding still needs more investigation, and recommendations for the vaccine have not been changed, a statement by the U.S. Food and Drug Administration said.

China in talks with Pfizer for generic COVID drug

Asia Pacific / Science & Health Jan 7, 2023

China in talks with Pfizer for generic COVID drug

Beijing is in talks with the drugmaker to secure a license that will allow domestic firms to manufacture and distribute a generic version of its Paxlovid antiviral drug.

Pfizer’s RSV vaccine succeeds where others failed

Commentary / World Nov 21, 2022

Pfizer’s RSV vaccine succeeds where others failed

by Lisa Jarvis

Early data bodes well for Pfizer’s RSV shot, which would be given during pregnancy to protect infants in the early months of life.

Pfizer’s Paxlovid anti-viral seen to lower long-COVID risk in study

World / Science & Health Nov 7, 2022

Pfizer’s Paxlovid anti-viral seen to lower long-COVID risk in study

by Jason Gale

Taking the oral medication within five days of testing positive for a SARS-CoV-2 infection was linked to a 26% lower risk of lingering post-viral complications, researchers found.

Study shows new booster improves protection for older people, Pfizer says

World / Science & Health Nov 5, 2022

Study shows new booster improves protection for older people, Pfizer says

by Sharon Lafraniere

U.S. officials are hoping that the encouraging results will improve what has so far been a dismal public response to the retooled shots.

Japan health ministry backs Pfizer and Moderna omicron boosters

National Sep 12, 2022

Japan health ministry backs Pfizer and Moderna omicron boosters

Pfizer’s omicron booster can be administered to people age 12 and over, while Moderna’s is limited to those 18 and above, the panel advised.

What we know about the new omicron vaccines

National / Science & Health | EXPLAINER Aug 12, 2022

What we know about the new omicron vaccines

by Kanako Takahara

New vaccines developed for the COVID-19 omicron variant are scheduled to be available from mid-October in Japan, raising hopes that the population will soon be better protected.

Shionogi confirms efficacy of oral COVID drug for omicron subvariant

National Aug 10, 2022

Shionogi confirms efficacy of oral COVID drug for omicron subvariant

The announcement came after a health ministry panel in July postponed the granting of emergency approval for the drug.

Pfizer to buy Global Blood Therapeutics in $5.4 billion deal

Business / Corporate Aug 9, 2022

Pfizer to buy Global Blood Therapeutics in $5.4 billion deal

Pfizer will gain Oxbryta, South San Francisco-based Global Blood’s therapy for sickle-cell disease that sold about $195 million last year.

We need better COVID-19 booster shots, not more of the same

Commentary / World Apr 11, 2022

We need better COVID-19 booster shots, not more of the same

by Faye Flam

There are 100 new Covid vaccines in development. One of them could offer better protection against omicron.

China promotes traditional cures as Pfizer pill alternatives

Asia Pacific / Science & Health Apr 4, 2022

China promotes traditional cures as Pfizer pill alternatives

China is struggling to persuade skeptics to put aside doubts about traditional medicine that hasn’t gone through large, standardized clinical trials.

VIEW OLDER ARTICLES

  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times